Breaking News

BioMerieux, Quanterix In Strategic Immunoassay Pact

November 16, 2012

Will develop ultra-sensitive and multiplex assays

BioMerieux and Quanterix have entered into a strategic agreement that gives BioMerieux exclusive rights to Quanterix's Simoa technology in clinical labs and for industrial applications. BioMerieux will develop ultra-sensitive and multiplex assays using the Simoa platform, with a particular focus on infectious diseases. Quanterix will receive upfront and milestone payments, as well as royalties on future sales. Additionally, BioMerieux has taken an initial $15 million equity stake in Quanterix.
The Simoa technology is based on a digital approach that enables detection of a signal from single molecules of a labelled analyte, and is much more sensitive than conventional analog-based protein detection technologies, according to the company.
"This agreement marks an important milestone for our immunoassay franchise, strengthening our role as a specialized player with a ground-breaking technology that delivers significant medical value," said Jean-Luc Belingard, chairman and chief executive officer of BioMerieux. "We have great admiration for Quanterix's achievement in developing a technology with the sensitivity of molecular diagnostics at a more affordable cost. We are very pleased to make this breakthrough available to a broad number of laboratories."
"BioMerieux's partnership validates the incredible foundation the Quanterix team has developed and will make it possible for this remarkable technology to make a difference in the lives of patients," said Paul Chapman, president and chief executive officer of Quanterix. "As one of the leading companies in the IVD space, we could not have found a better strategic partner to develop and commercialize Simoa in this critical market segment."
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks